Prescription Drug Supply Chain Pricing Transparency Act
12/19/2024, 9:06 AMSummary of Bill HR 7535
Bill 118 HR 7535, also known as the Prescription Drug Supply Chain Pricing Transparency Act, aims to increase transparency in the pricing of prescription drugs within the supply chain. The bill requires drug manufacturers, wholesalers, and pharmacies to disclose information about the prices they charge for prescription drugs, including the cost of production, distribution, and any discounts or rebates offered.The goal of the bill is to shed light on the often opaque pricing practices within the prescription drug supply chain, which can lead to higher costs for consumers. By requiring greater transparency, the bill seeks to empower consumers to make more informed decisions about their healthcare and potentially lower the cost of prescription drugs.
Additionally, the bill includes provisions to protect confidential information and trade secrets, ensuring that sensitive business information is not disclosed to competitors. It also establishes penalties for non-compliance with the transparency requirements, in order to incentivize compliance and ensure the effectiveness of the legislation. Overall, the Prescription Drug Supply Chain Pricing Transparency Act aims to promote fairness and accountability within the prescription drug supply chain, ultimately benefiting consumers by increasing transparency and potentially lowering the cost of prescription drugs.
Read the Full Bill
Current Status of Bill HR 7535
Bill HR 7535 is currently in the status of Bill Introduced since March 5, 2024. Bill HR 7535 was introduced during Congress 118 and was introduced to the House on March 5, 2024. Bill HR 7535's most recent activity was Referred to the Subcommittee on Health. as of December 17, 2024Bipartisan Support of Bill HR 7535
Total Number of Sponsors
2Democrat Sponsors
2Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
1Democrat Cosponsors
0Republican Cosponsors
1Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 7535
Primary Policy Focus
HealthAlternate Title(s) of Bill HR 7535
Prescription Drug Supply Chain Pricing Transparency ActTo require the Comptroller General of the United States to conduct a study and submit a report on price-related compensation and payment structures in the prescription drug supply chain.Prescription Drug Supply Chain Pricing Transparency ActComments
Most relevant
Sponsors and Cosponsors of HR 7535
Latest Bills
Law Enforcement Support and Counter Transnational Repression Act
Bill HR 2116April 1, 2025
District of Columbia Local Funds Act, 2025
Bill S 1077April 1, 2025
Veterans SPORT Act
Bill HR 1971April 1, 2025
Simplifying Veterans Assistance Act of 2025
Bill HR 1960April 1, 2025
Fairness in Veterans’ Education Act
Bill HR 1872April 1, 2025
VA Home Loan Program Reform Act
Bill HR 1815April 1, 2025
Restoring the VA Home Loan Program in Perpetuity Act of 2025
Bill HR 1814April 1, 2025
Fair Access to Co-ops for Veterans Act of 2025
Bill HR 1803April 1, 2025
Veterans Readiness and Employment Transparency Act of 2025
Bill HR 1793April 1, 2025
Copay Fairness for Veterans Act
Bill HR 1644April 1, 2025
Modernizing and Ensuring PBM Accountability Act
Bill S 2973December 23, 2023
Prescription Drug Supply Chain Pricing Transparency Act
Bill S 2198March 13, 2024